{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T17:18:47Z","timestamp":1712942327919},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.2169\/internalmedicine.1255-22","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T22:14:09Z","timestamp":1681424049000},"page":"3507-3510","source":"Crossref","is-referenced-by-count":1,"title":["Lung Injury Induced by Crizotinib and Entrectinib in a Patient with &lt;i&gt;ROS1&lt;\/i&gt;-rearranged Non-small-cell Lung Cancer"],"prefix":"10.2169","volume":"62","author":[{"given":"Yoshiki","family":"Nishiyama","sequence":"first","affiliation":[{"name":"Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[{"name":"Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Komiya","sequence":"additional","affiliation":[{"name":"Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tanimura M, Kataoka N, Kunimatsu Y, et al. Entrectinib for ROS1-rearranged non-small cell lung cancer after crizotinib-induced interstitial lung disease: a case report. Respirol Case Rep 9: e0857, 2021.","DOI":"10.1002\/rcr2.857"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hwang HJ, Kim MY, Choi CM, Lee JC. Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: clinical and radiologic characteristics and risk factors. Medicine 98: 48, 2019.","DOI":"10.1097\/MD.0000000000018131"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yoneda KY, Scranton JR, Cadogan MA, et al. Interstitial lung disease associated with crizotinib in patients with advanced non- small cell lung cancer: independent review of four PROFILE trials. Clin Lung Cancer 18: 472-479, 2017.","DOI":"10.1016\/j.cllc.2017.03.004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in <i>ROS1<\/i>-rearranged non-small-cell lung cancer. N Engl J Med 371: 1963-1971, 2014.","DOI":"10.1056\/NEJMoa1406766"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wu YL, Yang JC, Kim DW, et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol 36: 1405-1411, 2018.","DOI":"10.1200\/JCO.2017.75.5587"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Landi L, Chiari R, Tiseo M, et al. Crizotinib in <i>MET<\/i>-deregulated or <i>ROS1<\/i>-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial. Clin Cancer Res 25: 7312-7319, 2019.","DOI":"10.1158\/1078-0432.CCR-19-0994"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Michels S, Massut\u00ed B, Schildhaus HU, et al. Safety and efficacy of crizotinib in patients with advanced or metastatic <i>ROS1<\/i>-rearranged lung cancer (EUCROSS): a European phase II clinical trial. J Thorac Oncol 14: 1266-1276, 2019.","DOI":"10.1016\/j.jtho.2019.03.020"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Drilon A, Chiu CH, Fan Y, et al. Long-term efficacy and safety of entrectinib in <i>ROS1<\/i> fusion-positive NSCLC. JTO Clin Res Rep 3: 100332, 2022.","DOI":"10.1016\/j.jtocrr.2022.100332"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cr\u00e9quit P, Wislez M, Fleury JF, et al. Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review. J Thorac Oncol 10: 1148-1155, 2015.","DOI":"10.1097\/JTO.0000000000000577"},{"key":"10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2018.03.014","volume":"119","author":"M Domenech","year":"2018","unstructured":"10. Domenech M, Jove M, Aso S, Marin M, Nadal E. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease. Lung Cancer 119: 99-102, 2018.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Chino H, Sekine A, Kitamura H, Kato T, Ogura T. Successful treatment with alectinib after crizotinib-induced interstitial lung disease. Lung Cancer 90: 610-613, 2015.","DOI":"10.1016\/j.lungcan.2015.09.019"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kaira K, Naruse I, Shimizu K, Asao T. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib. J Can Res Ther 16: 919-921, 2020.","DOI":"10.4103\/jcrt.JCRT_985_15"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/23\/62_1255-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T03:18:37Z","timestamp":1701487117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/23\/62_1255-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":12,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1255-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1255-22"}}